FINCH THERAPEUTICS GROUP INC (FNCH) Stock Price & Overview
NASDAQ:FNCH • US31773D2009
Current stock price
The current stock price of FNCH is 1.8 USD. Today FNCH is down by -9.09%. In the past month the price decreased by -22.41%. In the past year, price decreased by -78.26%.
FNCH Key Statistics
- Market Cap
- 2.898M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -10.15
- Dividend Yield
- N/A
FNCH Stock Performance
FNCH Stock Chart
FNCH Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to FNCH. When comparing the yearly performance of all stocks, FNCH is a bad performer in the overall market: 95.63% of all stocks are doing better.
FNCH Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FNCH. The financial health of FNCH is average, but there are quite some concerns on its profitability.
FNCH Earnings
FNCH Forecast & Estimates
7 analysts have analysed FNCH and the average price target is 91.8 USD. This implies a price increase of 5000% is expected in the next year compared to the current price of 1.8.
For the next year, analysts expect an EPS growth of 45.96% and a revenue growth -100% for FNCH
FNCH Groups
Sector & Classification
FNCH Financial Highlights
Over the last trailing twelve months FNCH reported a non-GAAP Earnings per Share(EPS) of -10.15. The EPS increased by 89.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.51% | ||
| ROE | -85.55% | ||
| Debt/Equity | 0 |
FNCH Ownership
FNCH Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.82 | 362.599B | ||
| AMGN | AMGEN INC | 15.24 | 187.489B | ||
| GILD | GILEAD SCIENCES INC | 15.52 | 170.335B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.42 | 115.33B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.68 | 77.479B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.84 | 41.4B | ||
| INSM | INSMED INC | N/A | 29.315B | ||
| NTRA | NATERA INC | N/A | 27.677B | ||
| BIIB | BIOGEN INC | 11.29 | 26.631B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.55 | 22.979B | ||
| MRNA | MODERNA INC | N/A | 20.292B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 20.026B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.981B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About FNCH
Company Profile
Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. The company is headquartered in Boston, Massachusetts and currently employs 18 full-time employees. The company went IPO on 2021-03-19. The company is focused on realizing the value of its intellectual property estate and other assets, while supporting the advancement of its microbiome technology through partnerships and collaborations. The company has an intellectual property estate, including more than 70 issued U.S. and foreign patents with relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The Company’s assets include CP101, an orally administered microbiome candidate designed for the prevention of recurrent C. difficile infection (CDI), with positive clinical data from a Phase II randomized, placebo-controlled trial and a Phase II open-label trial, and pre-clinical assets that are designed to target ulcerative colitis, Crohn’s disease, and autism spectrum disorder. Additionally, it has also developed a biorepository of strains and samples.
Company Info
IPO: 2021-03-19
FINCH THERAPEUTICS GROUP INC
75 State Street, Suite 100
Boston MASSACHUSETTS US
Employees: 18
Phone: 16172296499
FINCH THERAPEUTICS GROUP INC / FNCH FAQ
What does FNCH do?
Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. The company is headquartered in Boston, Massachusetts and currently employs 18 full-time employees. The company went IPO on 2021-03-19. The company is focused on realizing the value of its intellectual property estate and other assets, while supporting the advancement of its microbiome technology through partnerships and collaborations. The company has an intellectual property estate, including more than 70 issued U.S. and foreign patents with relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The Company’s assets include CP101, an orally administered microbiome candidate designed for the prevention of recurrent C. difficile infection (CDI), with positive clinical data from a Phase II randomized, placebo-controlled trial and a Phase II open-label trial, and pre-clinical assets that are designed to target ulcerative colitis, Crohn’s disease, and autism spectrum disorder. Additionally, it has also developed a biorepository of strains and samples.
What is the current price of FNCH stock?
The current stock price of FNCH is 1.8 USD. The price decreased by -9.09% in the last trading session.
Does FNCH stock pay dividends?
FNCH does not pay a dividend.
What is the ChartMill rating of FINCH THERAPEUTICS GROUP INC stock?
FNCH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about FINCH THERAPEUTICS GROUP INC (FNCH) stock?
7 analysts have analysed FNCH and the average price target is 91.8 USD. This implies a price increase of 5000% is expected in the next year compared to the current price of 1.8.
Would investing in FINCH THERAPEUTICS GROUP INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on FNCH.
What is FINCH THERAPEUTICS GROUP INC worth?
FINCH THERAPEUTICS GROUP INC (FNCH) has a market capitalization of 2.90M USD. This makes FNCH a Nano Cap stock.